News & Publications

The 2024 M&A Report takes a good look at the global M&A market, covering everything from trends to key insights.

The 2024 Venture Capital Report takes a deep dive into the US venture capital market, covering everything from regional and industry breakdowns to insights on important topics.

The 2024 IPO Report takes a close look at the IPO market and shares useful market metrics and need-to-know information on topics that affect pre-IPO companies.

WilmerHale’s annual IPO, Venture Capital and M&A reports offer detailed insights into market conditions and provide comprehensive statistics and thoughtful analysis.

WilmerHale represented Siolta Therapeutics, Inc., a biotech company developing live biotherapeutics that target the core drivers of disease, in its $12 million Series C Preferred Stock financing. 

In 2023, we served as counsel in more than 150 venture financings raising over $4 billion, including some of the largest and most prominent deals of the year.

Together, WilmerHale and Cornell University have collaborated in a joint effort to publish Startup Launch – Liftoff with Legal 101 for Entrepreneurs, a booklet for startup founders to think early about key items that will set them off on the right legal track.

LMG Life Sciences has named WilmerHale as the Venture Capital Firm of the Year in its 11th annual awards. 

On August 9, 2023, Georgiamune Inc., a privately held, clinical stage biotechnology company, announced the clearance of its Investigational New Drug application by the US Food and Drug Administration for GIM-122, a dual-functioning monoclonal antibody. 

The 2023 M&A Report provides a broad, global M&A market review and outlook, plus insights on several important topics.

The 2023 Venture Capital Report offers an in-depth US venture capital market review and outlook, including regional and industry breakdowns, along with insights on key topics.

The 2023 IPO Report shares a detailed look at the IPO market and provides useful market metrics and need-to-know information on topics that affect pre-IPO companies.

WilmerHale’s annual IPO, Venture Capital and M&A reports offer detailed insights into market conditions and provide comprehensive statistics and thoughtful analysis.

In 2022, we served as counsel in more than 200 venture financings raising over $7 billion, including some of the largest and most prominent deals of the year.

On November 14, MBX Biosciences, a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing round led by Wellington Management, which was represented by WilmerHale.